Immunome Inc. (IMNM)

Pharmaceutical Preparations · market cap $2.8B · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Immunome Inc. (IMNM) is a clinical-stage pharmaceutical company with a market cap of ~$2.6B and a single disclosed lead asset, AL102, currently in Phase 3 trials for desmoid tumors. The company holds $582.7M in cash with a runway of approximately 30 months, providing near-term financial stability. The upcoming August 5, 2026 earnings call represents the next scheduled public-facing event, though no near-term trial readout catalyst is explicitly flagged.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
AL102	Phase 3	Desmoid

Price & technical context

3-month

-11.5%

6-month

-6.9%

12-month

+78.4%

52-wk range

$11.34–$29.83

vs 50-day MA

-17.4%

vs 200-day MA

-8.2%

Realized vol

63.8%

Max drawdown

-65.2%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for IMNM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.